BR112022003852A2 - Métodos de preparação de células t para terapia de células t - Google Patents
Métodos de preparação de células t para terapia de células tInfo
- Publication number
- BR112022003852A2 BR112022003852A2 BR112022003852A BR112022003852A BR112022003852A2 BR 112022003852 A2 BR112022003852 A2 BR 112022003852A2 BR 112022003852 A BR112022003852 A BR 112022003852A BR 112022003852 A BR112022003852 A BR 112022003852A BR 112022003852 A2 BR112022003852 A2 BR 112022003852A2
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- preparing
- methods
- cell therapy
- cell
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 238000002659 cell therapy Methods 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 238000012258 culturing Methods 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
métodos de preparação de células t para terapia de células t. são fornecidos neste documento métodos para preparar células t para terapia de células t compreendendo o contato de uma população de células em uma densidade celular predeterminada, com uma concentração de uma nanomatriz anti-cd3/cd28 e a cultura das células produzindo, assim, uma população de células t compreendendo uma porcentagem aumentada de pelo menos um subtipo de célula t. em algumas modalidades, o método aumenta a porcentagem de células t tronco de memória.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895381P | 2019-09-03 | 2019-09-03 | |
| PCT/US2020/049074 WO2021046134A1 (en) | 2019-09-03 | 2020-09-02 | Methods of preparing t cells for t cell therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022003852A2 true BR112022003852A2 (pt) | 2022-05-31 |
Family
ID=72521739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022003852A BR112022003852A2 (pt) | 2019-09-03 | 2020-09-02 | Métodos de preparação de células t para terapia de células t |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210062150A1 (pt) |
| EP (1) | EP4025688A1 (pt) |
| JP (1) | JP2022546537A (pt) |
| KR (1) | KR20220054383A (pt) |
| CN (1) | CN114341348A (pt) |
| AU (1) | AU2020343300A1 (pt) |
| BR (1) | BR112022003852A2 (pt) |
| CA (1) | CA3147441A1 (pt) |
| IL (1) | IL291074A (pt) |
| MX (1) | MX2022002527A (pt) |
| WO (1) | WO2021046134A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113046306B (zh) * | 2021-03-12 | 2022-10-18 | 广东东阳光药业有限公司 | 一种多能干细胞的培养方法 |
| WO2022215718A1 (ja) * | 2021-04-08 | 2022-10-13 | 武田薬品工業株式会社 | Ｔ細胞活性化方法 |
| US20230027004A1 (en) * | 2021-07-01 | 2023-01-26 | Kite Pharma, Inc. | Closed-system and method for autologous and allogeneic cell therapy manufacturing |
| WO2023232745A1 (en) * | 2022-05-30 | 2023-12-07 | Mediterranea Theranostic S.R.L. | Anti-idiotype antibodies and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| KR102243575B1 (ko) | 2010-12-09 | 2021-04-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
| BR112013018311A2 (pt) | 2011-01-18 | 2017-03-21 | Univ Pennsylvania | sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada. |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| AU2012308205A1 (en) | 2011-09-16 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
| EP2711418B1 (en) | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| EP3134512B1 (en) * | 2014-04-24 | 2019-01-02 | Miltenyi Biotec GmbH | Method for automated generation of genetically modified t cells |
-
2020
- 2020-09-02 BR BR112022003852A patent/BR112022003852A2/pt unknown
- 2020-09-02 CA CA3147441A patent/CA3147441A1/en active Pending
- 2020-09-02 AU AU2020343300A patent/AU2020343300A1/en active Pending
- 2020-09-02 KR KR1020227010430A patent/KR20220054383A/ko unknown
- 2020-09-02 MX MX2022002527A patent/MX2022002527A/es unknown
- 2020-09-02 JP JP2022514011A patent/JP2022546537A/ja active Pending
- 2020-09-02 US US17/010,707 patent/US20210062150A1/en active Pending
- 2020-09-02 WO PCT/US2020/049074 patent/WO2021046134A1/en active Application Filing
- 2020-09-02 CN CN202080062376.9A patent/CN114341348A/zh active Pending
- 2020-09-02 EP EP20772503.7A patent/EP4025688A1/en active Pending
-
2022
- 2022-03-02 IL IL291074A patent/IL291074A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020343300A1 (en) | 2022-03-03 |
| WO2021046134A1 (en) | 2021-03-11 |
| IL291074A (en) | 2022-05-01 |
| CN114341348A (zh) | 2022-04-12 |
| WO2021046134A9 (en) | 2021-10-07 |
| JP2022546537A (ja) | 2022-11-04 |
| CA3147441A1 (en) | 2021-03-11 |
| EP4025688A1 (en) | 2022-07-13 |
| US20210062150A1 (en) | 2021-03-04 |
| KR20220054383A (ko) | 2022-05-02 |
| MX2022002527A (es) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022003852A2 (pt) | Métodos de preparação de células t para terapia de células t | |
| EA201992795A1 (ru) | Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе | |
| BR112019008560A2 (pt) | célula artificial que apresenta antígeno, método para expandir linfócitos infiltrantes de tumor, para tratar um câncer com uma população de linfócitos infiltrantes de tumor e para avaliar a potência de linfócitos infiltrantes de tumor, kit, população de linfócitos infiltrantes de tumor, e, combinação | |
| MX2019015021A (es) | Metodo de fabricacion de anticuerpos biespecificos, anticuerpos biespecificos y uso terapeutico de dichos anticuerpos. | |
| EA202090931A2 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
| BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
| TR201900776T4 (tr) | Memeli hücre kültürlerinin hasadına ilişkin yöntem. | |
| MX2023005612A (es) | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. | |
| BR112015027996A8 (pt) | Organoides compreendendo células renais isoladas e suas utilizações | |
| CY1124672T1 (el) | Μεθοδοι αποθηκευσης τραπεζων κυτταρων εξαιρετικα υψηλης πυκνοτητας | |
| MX2021005021A (es) | Proceso para producir celulas t geneticamente modificadas. | |
| TR201908404T4 (tr) | İşlenmiş yüksek afinite insan t hücresi reseptörleri. | |
| BR112016028512A8 (pt) | método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante | |
| MX2020005908A (es) | Proceso para producir una composicion de celulas t modificadas. | |
| MX2021011816A (es) | Metodos para produccion de celulas car-nk y uso de las mismas. | |
| CO2022007238A2 (es) | Terapia de células t del receptor de antígeno quimérico | |
| CL2020000734A1 (es) | Expansión y uso de fracciones de células nk ampliadas. | |
| AU2018335876A1 (en) | In situ combinatorial labeling of cellular molecules | |
| MX2015014892A (es) | Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo. | |
| ZA202205927B (en) | Anti-yellow fever virus antibodies, and methods of their generation and use | |
| BR112021024946A2 (pt) | Célula de mamífero, método para produzir uma célula de mamífero implantável, e, uso de uma célula de mamífero | |
| ATE514784T1 (de) | Zellpräparation | |
| EA201992875A1 (ru) | T-клетки со сниженным поверхностным фукозилированием и способы их получения и применения | |
| WO2019066617A3 (ko) | 항 c-met 항체 및 이의 용도 | |
| CO2021007824A2 (es) | Gen suicida |